HHLA2 and intrahepatic cholangiocarcinoma: These results were consistent with previous reports showing that HHLA2 was overexpressed in a variety of cancer cells (25, 36, 37) and could also independently portend patient outcomes in clear cell renal cell carcinoma and intrahepatic cholangiocarcinoma (25, 38).